Shots:

• The P-III (JAVELIN Bladder 100) trial evaluates Bavencio + BSC vs BSC alone in patients with LA or metastatic UC
• The results of an exploratory analysis with 19 additional follow-up data from the initial primary analysis, patients showed an overall survival benefit @38mos. median follow-up, m-OS (23.8mos. vs 15.0mos.), 43.7% vs 33.5% were alive @30mos.
• In patients with PD-L1+ tumors, m-OS (30.9mos. vs 18.5mos.), 51.3% vs 38.5% were alive @30mos. & the safety profile was consistent with the overall clinical development program with no new safety signals. In the primary population of all randomized patients,19.5% received ≥2yrs. of treatment & 10.2% discontinuing due to TRAEs @ ≥12mos.

 Ref: Businesswire | Image: EMD Group